MATILDE chemotherapy regimen for primary CNS lymphoma: Results at a median follow-up of 12 years, Neurology, vol.82, issue.15, pp.1370-1373, 2014. ,
DOI : 10.1212/WNL.0000000000000314
Intensive Chemotherapy and Immunotherapy in Patients With Newly Diagnosed Primary CNS Lymphoma: CALGB 50202 (Alliance 50202), Journal of Clinical Oncology, vol.31, issue.25, pp.3061-3068, 2013. ,
DOI : 10.1200/JCO.2012.46.9957
Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment, Blood, vol.101, issue.2, pp.466-468, 2003. ,
DOI : 10.1182/blood-2002-06-1636
Rituximab monotherapy for patients with recurrent primary CNS lymphoma, Neurology, vol.76, issue.10, pp.929-930, 2011. ,
DOI : 10.1212/WNL.0b013e31820f2d94
Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology, The Lancet Oncology, vol.16, issue.7, pp.322-332, 2015. ,
DOI : 10.1016/S1470-2045(15)00076-5
Phase I Study of Intraventricular Administration of Rituximab in Patients With Recurrent CNS and Intraocular Lymphoma, Journal of Clinical Oncology, vol.25, issue.11, pp.1350-1356, 2007. ,
DOI : 10.1200/JCO.2006.09.7311
Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma, Blood, vol.121, issue.5, pp.745-751, 2013. ,
DOI : 10.1182/blood-2012-07-440974
Complement Activation and Intraventricular Rituximab Distribution in Recurrent Central Nervous System Lymphoma, Clinical Cancer Research, vol.20, issue.4, pp.1029-1041, 2013. ,
DOI : 10.1158/1078-0432.CCR-13-0474
Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue for Refractory and Recurrent Primary CNS and Intraocular Lymphoma: Soci??t?? Fran??aise de Greffe de Mo??lle Osseuse-Th??rapie Cellulaire, Journal of Clinical Oncology, vol.26, issue.15, pp.2512-2518, 2008. ,
DOI : 10.1200/JCO.2007.13.5533
High-dose chemotherapy and autologous stem-cell transplantation without consolidating 62-Montesinos-Rongen Gene expression profiling suggests primary central nervous system lymphomas to be derived from a late germinal center B cell, Leukemia, vol.22, pp.400-405, 2008. ,
Bcl-6 predicts improved prognosis in primary central nervous system lymphoma, Cancer, vol.24, issue.1, pp.151-156, 2008. ,
DOI : 10.1002/cncr.23149
BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma, Clin Cancer Res, vol.9, pp.1063-1069, 2003. ,
Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma, Blood, vol.90, pp.244-251, 1997. ,
Frequent triple-hit expression of MYC, BCL2, and BCL6 in primary lymphoma of the central nervous system and absence of a favorable MYClowBCL2low subgroup may underlie the inferior prognosis as compared to systemic diffuse large B cell lymphomas, Acta Neuropathologica, vol.346, issue.4, pp.603-605, 2013. ,
DOI : 10.1007/s00401-013-1169-7
Rare occurrence of inactivating p53 gene mutations in primary non-astrocytic tumors of the central nervous system: reappraisal by yeast functional assay, Acta Neuropathologica, vol.95, issue.3, pp.291-296, 1998. ,
DOI : 10.1007/s004010050800
Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma, New England Journal of Medicine, vol.362, issue.10, pp.875-885, 2010. ,
DOI : 10.1056/NEJMoa0905680
An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, Leukemia & Lymphoma, vol.55, issue.11 ,
DOI : 10.4049/jimmunol.0713732
Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial, Haematologica, vol.100, issue.2, pp.238-245, 2015. ,
DOI : 10.3324/haematol.2014.113472
CD4+ T-Cell Immune Response to Large B-Cell Non-Hodgkin???s Lymphoma Predicts Patient Outcome, Journal of Clinical Oncology, vol.19, issue.3 ,
DOI : 10.1200/JCO.2001.19.3.720
Reactive perivascular T-cell infiltrate predicts survival in primary central nervous system B-cell lymphomas, British Journal of Haematology, vol.5, issue.3, pp.316-323, 2007. ,
DOI : 10.1038/nrc1586
Immune adaptive microenvironment profiles in intracerebral and intrasplenic lymphomas share common characteristics, Clinical & Experimental Immunology, vol.453, issue.3, pp.329-337, 2011. ,
DOI : 10.1111/j.1365-2249.2011.04416.x
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma, New England Journal of Medicine, vol.372, issue.4, pp.311-319, 2015. ,
DOI : 10.1056/NEJMoa1411087
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial, The Lancet Oncology, vol.15, issue.1, pp.69-77, 2014. ,
DOI : 10.1016/S1470-2045(13)70551-5
PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL), PD1 (CD279) and PD-L1 (CD274,B7H1) expression in primary central nervous system lymphomas (PCNSL), pp.42-49, 2014. ,
DOI : 10.5414/NP300698
Expression of the FoxP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma, Clin Cancer Res, vol.11, pp.1065-1072, 2005. ,